Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis

Arthritis and Rheumatism

Volumn 60, Issue 11, 2009, Pages 3225-3228

  Fleischmann, R M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; ETODOLAC; FLUORODEOXYGLUCOSE F 18; HYDROXYCHLOROQUINE; INFLIXIMAB; MEPREDNISONE; METHOTREXATE; PREDNISONE; RITUXIMAB;

ADULT; ANAMNESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CLINICAL FEATURE; DRUG DOSE INCREASE; FEMALE; HUMAN; LABORATORY TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OROPHARYNX CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MIDDLE AGED; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70350539709     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24906     Document Type: Article

References (21)

1. Berger JR. Progressive multifocal leukoencephalopathy. Curr Neurol Neurosci Rep 2007;7:461-469
2. Boren EJ, Cheema GS, Naguwa SM, Ansari AA, Gershwin ME. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 2008;30:90-98
3. Major EO, Amemiya K, Tornatore CS, Houff SA, Berger JR. Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev 1992;5:49-73.
4. Selik RM, Karon JM, Ward JW. Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993. J Infect Dis 1997;176:632-636
5. Berger JR. Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis 2006;65 Suppl 3:iii48-53.
6. Genentech Inc. Important drug warning regarding Raptiva (efalizumab). URL: http://www.gene.com/gene/products/information/ pdf/raptiva-dhcp-pml3.pdf. February 10, 2009.
7. Calabrese LH, Molloy ES, Huang D, Ransohoff RM. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease [review]. Arthritis Rheum 2007;56:2116-2128 (Pubitemid 47173558)
8. Harris HE. Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology (Oxford) 2008;47:224-225 (Pubitemid 351168240)
9. US Food and Drug Administration. Public health advisory: life-threatening brain infection in patients with systemic lupus erythematosus after Rituxan (rituximab) treatment. URL: http:// www.fda.gov/Drugs/DrugSafety/ PublicHealthAdvisories/ucm 124345.htm. Updated June 18, 2009.
10. Genentech Inc. Rituximab new safety information. URL: www. fda.gov/medwatch/safety/2008/rituxan-DHCP-Final%209411700. pdf.
11. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al, for the REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-2806
12. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48
13. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-735
14. Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007;47:1119-1128
15. Fleischmann RM. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum 2009;38:265-280
16. Van Vollenhoven RF, Emery P, Bingham CO III, Keystone E, Fleischmann R, Furst DE, et al. Long-term safety of rituximab: 6-year follow-up of the RA clinical trials and re-treatment population [abstract]. Arthritis Rheum 2008;58 Suppl 9:S300.
17. Rahmlow M, Shuster E, Dominik J, Deen H, Dickson D, Aksamit A, et al. Leflunomide-associated progressive multifocal leukoencephalopathy. Arch Neurol 2008;65:1538-1539
18. Marzocchetti A, Wuthrich C, Tan CS, Tompkins T, Bernal Cano F, Bhargava P, et al. Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy. J Neurovirol 2008;14:455-458 (Pubitemid 352762885)
19. Sponzilli E, Smith J, Malamud N, McCulloch J. Progressive multifocal leukoencephalopathy: a complication of immunosuppressive treatment. Neurology 1975;25:664-668
20. US Food and Drug Administration. Reporting by health professionals. URL: http://www.fda.gov/medwatch/report/hcp.htm.
21. Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy - a national estimate of frequency in SLE and other rheumatic diseases [abstract]. Arthritis Rheum 2008;58 Suppl 9:S637.